DK1079832T3 - Anvendelse af vitamin-PP-forbindelser - Google Patents
Anvendelse af vitamin-PP-forbindelserInfo
- Publication number
- DK1079832T3 DK1079832T3 DK99922119T DK99922119T DK1079832T3 DK 1079832 T3 DK1079832 T3 DK 1079832T3 DK 99922119 T DK99922119 T DK 99922119T DK 99922119 T DK99922119 T DK 99922119T DK 1079832 T3 DK1079832 T3 DK 1079832T3
- Authority
- DK
- Denmark
- Prior art keywords
- compounds
- vitamin
- pellagra
- activity
- formula
- Prior art date
Links
- 125000000627 niacin group Chemical class 0.000 title 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical class NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 206010029400 Nicotinic acid deficiency Diseases 0.000 abstract 2
- 208000002141 Pellagra Diseases 0.000 abstract 2
- 238000002512 chemotherapy Methods 0.000 abstract 2
- 235000005152 nicotinamide Nutrition 0.000 abstract 2
- 239000011570 nicotinamide Substances 0.000 abstract 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 229960003966 nicotinamide Drugs 0.000 abstract 1
- 229960003512 nicotinic acid Drugs 0.000 abstract 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009467 reduction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19818044A DE19818044A1 (de) | 1998-04-22 | 1998-04-22 | Verwendung von Vitamin-PP-Verbindungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1079832T3 true DK1079832T3 (da) | 2006-04-03 |
Family
ID=7865483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99922119T DK1079832T3 (da) | 1998-04-22 | 1999-04-21 | Anvendelse af vitamin-PP-forbindelser |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20100227896A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1079832B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4607319B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE311186T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU3928299A (cg-RX-API-DMAC7.html) |
| DE (2) | DE19818044A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1079832T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2253890T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999053920A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000007580A2 (en) * | 1998-08-03 | 2000-02-17 | N-Gene Kutató Kft. | Pharmaceutical compositions against autoimmune diseases |
| GB0104240D0 (en) | 2001-02-21 | 2001-04-11 | Clariant Int Ltd | Copolymer composition having pigment like properties |
| EP1348434A1 (en) * | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
| US8067457B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| WO2007053499A2 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| WO2009072004A2 (en) * | 2007-09-26 | 2009-06-11 | Gemin X Pharmaceuticals Canada, Inc. | Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
| EP2213288A1 (en) * | 2009-01-30 | 2010-08-04 | Karl Welte | NAMPT and vitamin B3 for treating or preventing diseases |
| CA2768338A1 (en) | 2009-07-17 | 2011-01-20 | Topotarget A/S | Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors |
| US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
| US8791045B2 (en) | 2011-11-09 | 2014-07-29 | Kimberly-Clark Worldwide, Inc. | Non-tacky wetness indicator composition for application on a polymeric substrate |
| US9889222B2 (en) | 2011-11-09 | 2018-02-13 | Kimberly-Clark Worldwide, Inc. | Aqueous medium-sensitive coating compositions for triggered release of active ingredients and visual indication for wetness |
| US9585826B2 (en) | 2012-11-07 | 2017-03-07 | Kimberly-Clark Worldwide, Inc. | Triggerable compositions for two-stage, controlled release of active chemistry |
| HK1215579A1 (zh) | 2012-11-29 | 2016-09-02 | Karyopharm Therapeutics, Inc. | 被取代的2，3-二氫苯並呋喃基化合物和其用途 |
| DK3016946T3 (da) | 2013-07-03 | 2023-01-09 | Karyopharm Therapeutics Inc | Substituerede benzofuranyl- og benzoxazolylforbindelser og anvendelser deraf |
| US9994558B2 (en) | 2013-09-20 | 2018-06-12 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| US9119780B2 (en) | 2013-10-30 | 2015-09-01 | Kimberly-Clark Worldwide, Inc. | Triggerable compositions for two-stage, controlled release of proactive chemistry |
| WO2017031323A1 (en) | 2015-08-18 | 2017-02-23 | Karyopharm Therapeutics Inc. | (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer |
| US10858347B2 (en) | 2015-12-31 | 2020-12-08 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
| RU2651047C1 (ru) * | 2017-05-04 | 2018-04-18 | Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" | Лекарственная композиция цитопротекторного действия и способ ее получения |
| WO2019153007A2 (en) * | 2018-02-05 | 2019-08-08 | The Boaro Of Trustees Of The University Of Illinois | Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same |
| CN115177594B (zh) * | 2022-07-04 | 2023-08-15 | 武汉大学中南医院 | 一种阿昔替尼药物制剂及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3148115A (en) * | 1958-12-08 | 1964-09-08 | Horner Frank W Ltd | Potentiation of tumor-growth inhibition from deoxypyridoxine, testosterone, or 6-mercaptopurine, by 6-aminonicotinamide |
| JPH04103538A (ja) * | 1990-08-24 | 1992-04-06 | Ajinomoto Co Inc | 制癌剤副作用抑制剤 |
| US5547927A (en) * | 1993-05-28 | 1996-08-20 | Abbott Laboratories | Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy |
| FI970588A7 (fi) * | 1994-08-12 | 1997-04-11 | Wellstat Therapeutics Corp | Menetelmät verenmyrkytyksen tai tulehdussairauksien hoitamiseksi oksipuriininukleosideillä |
| JPH0881371A (ja) * | 1994-09-09 | 1996-03-26 | Suntory Ltd | 造血機能亢進剤 |
| EP0800829B2 (en) * | 1994-12-29 | 2012-07-25 | Chugai Seiyaku Kabushiki Kaisha | Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin |
| JP3119430B2 (ja) * | 1995-07-25 | 2000-12-18 | 大鵬薬品工業株式会社 | 水酸基ラジカル消去剤 |
| JP2860637B2 (ja) * | 1995-12-11 | 1999-02-24 | 末綱 陽子 | 新規なペプチドおよび活性化酸素阻害剤 |
| JP3836203B2 (ja) * | 1995-12-20 | 2006-10-25 | 日本臓器製薬株式会社 | 活性酸素・フリーラジカル消去剤 |
| DE19624668A1 (de) * | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| DE19624704A1 (de) * | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalkansäureamide |
| US6451816B1 (en) * | 1997-06-20 | 2002-09-17 | Klinge Pharma Gmbh | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
| DE19624659A1 (de) * | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| JPH1036260A (ja) * | 1996-07-18 | 1998-02-10 | Mitsui Norin Kk | 抗ガン剤の効力増強方法 |
| JPH1045594A (ja) * | 1996-07-30 | 1998-02-17 | Mitsubishi Gas Chem Co Inc | 活性酸素消去剤 |
-
1998
- 1998-04-22 DE DE19818044A patent/DE19818044A1/de not_active Ceased
-
1999
- 1999-04-21 WO PCT/EP1999/002686 patent/WO1999053920A1/en not_active Ceased
- 1999-04-21 AT AT99922119T patent/ATE311186T1/de active
- 1999-04-21 DK DK99922119T patent/DK1079832T3/da active
- 1999-04-21 EP EP99922119A patent/EP1079832B1/en not_active Expired - Lifetime
- 1999-04-21 AU AU39282/99A patent/AU3928299A/en not_active Abandoned
- 1999-04-21 JP JP2000544324A patent/JP4607319B2/ja not_active Expired - Fee Related
- 1999-04-21 DE DE69928660T patent/DE69928660T2/de not_active Expired - Lifetime
- 1999-04-21 ES ES99922119T patent/ES2253890T3/es not_active Expired - Lifetime
-
2010
- 2010-05-13 US US12/779,698 patent/US20100227896A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU3928299A (en) | 1999-11-08 |
| ATE311186T1 (de) | 2005-12-15 |
| WO1999053920A1 (en) | 1999-10-28 |
| US20100227896A1 (en) | 2010-09-09 |
| DE69928660T2 (de) | 2006-09-14 |
| DE19818044A1 (de) | 1999-10-28 |
| JP4607319B2 (ja) | 2011-01-05 |
| ES2253890T3 (es) | 2006-06-01 |
| EP1079832B1 (en) | 2005-11-30 |
| JP2002512190A (ja) | 2002-04-23 |
| EP1079832A1 (en) | 2001-03-07 |
| DE69928660D1 (de) | 2006-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1079832T3 (da) | Anvendelse af vitamin-PP-forbindelser | |
| ATE260910T1 (de) | 4-heteroaryl-tetrahydrochinoline und ihre verwendung als inhibitoren des cholesterin-ester- transfer-proteins (ctep) | |
| TR199700584A2 (xx) | Heterosiklik-kayna��k piridinler. | |
| NO20062633L (no) | Pyrazolderivater som proteinkinasemodulatorer | |
| DE502004006507D1 (de) | Imidazopyridazinon- und imidazopyridonderivate, deren herstellung und deren verwendung als arzneimittel | |
| WO2001014376A8 (en) | Novel spiro compounds | |
| NO20081003L (no) | 2-Aminopyrimidinderivater som modulatorer av histamin-H4-reseptoraktivitet | |
| NO20030637D0 (no) | 2-aminopyridinforbindelser og anvendelse derav som legemidler | |
| TW200604174A (en) | Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp) | |
| HRP20080664A2 (hr) | Supstituirani piridinski herbicidi | |
| MY137944A (en) | Specific glucocorticoid compounds having anti-inflammatory activity | |
| AU5438180A (en) | (piperidinylalky) quinazoline derivatives | |
| ATE537830T1 (de) | Nicotinamid derivate und ihre verwendung als therapeutika | |
| WO2008034736A3 (en) | Oxindole derivatives as anticancer agents | |
| BRPI0516981A (pt) | inibidores de mif | |
| TR200001452T2 (tr) | Bifenilamidin türevleri. | |
| IE43951L (en) | 1-benzazolylalkyl-4-substituted-piperdines | |
| ATE39357T1 (de) | Derivate von griseolicsaeure und ihre verwendung. | |
| NO20004273L (no) | Streptograminderivater, deres fremstilling samt preparater inneholdende forbindelsene | |
| BR0315869A (pt) | Uso de compostos de complexos de metais como catalisadores de oxidação | |
| DE60108089D1 (de) | Heterozyclische oder benzol derivate von liponsäure, deren herstellung und deren verwendung als heilmittel | |
| BRPI0415034A (pt) | derivados de aminopiridina como inibidores de não-sintase induzìveis | |
| DE69910568D1 (de) | Furopyridinderivate und ihre therapeutische verwendung | |
| NO20001758L (no) | FremgangsmÕter og blandinger for behandling av leddgikt | |
| ATE276259T1 (de) | Dihydroporphyrinderivate und ihre verwendung |